Isolagen to shutter its UK subsidiary

Exton, PA-based Isolagen is closing its UK operations, saying that sustaining more losses in Europe isn't in the company's best interests. The move affects about 80 positions. "The management and the board have determined that the best use of resources is to focus on advancing the U.S. pivotal Phase III clinical trial of the Isolagen Process for the treatment of certain facial wrinkles, and then, with regulatory agencies' agreement, initiate clinical studies in key strategic therapeutic and aesthetic areas," said CEO Nicholas L. Teti. 

- see the release from Isolagen

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.